We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Sponsor content
32 result(s) found, displaying 1 to 10
-
Australian public assessment report (AusPar)VOYDEYA (danicopan) is indicated as an add-on to ravulizumab or eculizumab for the treatment of the signs or symptoms of extravascular haemolysis in adult patients with paroxysmal nocturnal haemoglobinuria.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for VOYDEYA danicopan 100 mg film-coated tablets, bottle.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for VOYDEYA 50 + 100 mg film-coated tablets, composite bottle pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for VOYDEYA danicopan 100 mg film-coated tablets, blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for VOYDEYA 50 + 100 mg film-coated tablets, composite blister pack.
-
Apr-2025Prescription medicine evaluationActive ingredient: selumetinib sulfate.
-
Prescription medicine registrationActive ingredients: danicopan.
-
Australian public assessment report (AusPar)Koselugo (selumetinib sulfate) has been approved for the treatment of paediatric patients 2 years of age and older with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas.
-
Australian public assessment report (AusPar)Ultomiris (ravulizumab) has been approved for the treatment of adult patients with Neuromyelitis Optica Spectrum Disorder who are anti-aquaporin 4 antibody-positive.
-
Prescription medicine registrationActive ingredients: ravulizumab.